Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population

Journal of Clinical Virology

Volumn 51, Issue 2, 2011, Pages 136-138

  Wong, Oscar Gee Wan ^a   Lo, C K ^a   Szeto, Elaine ^a   Cheung, Annie Nga Yin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Abbott RealTime High Risk HPV test; Cervical cancer; Cervical cytology; HPV DNA test; Hybrid Capture 2

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; ASIAN; CLINICAL FEATURE; DISEASE COURSE; ETHNICITY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCREENING; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VIROLOGY; YOUNG ADULT;

EID: 79956336871     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.03.010     Document Type: Article

References (23)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
2. Wright T.C. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?. Clin Obstet Gynecol 2007, 50:313-323.
3. Sherman M.E., Schiffman M., Cox J.T. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002, 94:102-107.
4. Cheung A.N., Szeto E.F., Leung B.S., Khoo U.S., Ng A.W. Liquid-based cytology and conventional cervical smears: a comparison study in an Asian screening population. Cancer 2003, 99:331-335.
5. Cheung A.N., Szeto E.F., Ng K.M., Fong K.W., Yeung A.C., Tsun O.K., Khoo U.S., Chan K.Y., Ng A.W. Atypical squamous cells of undetermined significance on cervical smears: follow-up study of an Asian screening population. Cancer 2004, 102:74-80.
6. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., Arbyn M., Bosch F.X., Cuzick J., Dillner J., Heideman D.A., Snijders P.J. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
7. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 Suppl 3:S3/78-89.
8. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., Ratnam S., Coutlee F., Franco E.L. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
9. Huang S., Tang N., Mak W.B., Erickson B., Salituro J., Li Y., Krumpe E., Schneider G., Yu H., Robinson J., Abravaya K. Principles and analytical performance of Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45(Suppl. 1):S13-S17.
10. Kaliterna V., Lepej S.Z., Vince A. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. J Med Microbiol 2009, 58:1662-1663.
11. Cuzick J., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., Liddle S., Dina R., McCarthy J., Buckley H., Bergeron C., Soutter W.P., et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010, 82:1186-1191.
12. Tang N., Huang S., Erickson B., Mak W.B., Salituro J., Robinson J., Abravaya K., High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. J Clin Virol 2009, 45(Suppl. 1):S25-S28.
13. Halfon P., Benmoura D., Agostini A., Khiri H., Penaranda G., Martineau A., Blanc B. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. J Clin Virol 2010, 48:246-250.
14. Poljak M., Kovanda A., Kocjan B.J., Seme K., Jancar N., Vrtacnik-Bokal E. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. Acta Dermatovenerol Alp Panonica Adriat 2009, 18:94-103.
15. Huang S., Erickson B., Tang N., Mak W.B., Salituro J., Robinson J., Abravaya K. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol 2009, 45(Suppl. 1):S19-23.
16. Bory J.P., Cucherousset J., Lorenzato M., Gabriel R., Quereux C., Birembaut P., Clavel C. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3091 women. Int J Cancer 2002, 102:519-525.
17. Rodriguez A.C., Burk R., Herrero R., Hildesheim A., Bratti C., Sherman M.E., Solomon D., Guillen D., Alfaro M., Viscidi R., Morales J., Hutchinson M., et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007, 34:494-502.
18. Rodriguez A.C., Schiffman M., Herrero R., Hildesheim A., Bratti C., Sherman M.E., Solomon D., Guillen D., Alfaro M., Morales J., Hutchinson M., Katki H., et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102:315-324.
19. Einstein M.H., Martens M.G., Garcia F.A., Ferris D.G., Mitchell A.L., Day S.P., Olson M.C. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010, 118:116-122.
20. Chan P.K., Li W.H., Chan M.Y., Ma W.L., Cheung J.L., Cheng A.F. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999, 59:232-238.
21. Liu S.S., Tsang P.C., Chan K.Y., Cheung A.N., Chan K.K., Leung R.C., Ngan H.Y. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas. Tumour Biol 2008, 29:105-113.
22. Saito J., Fukuda T., Hoshiai H., Noda K. High-risk types of human papillomavirus associated with the progression of cervical dysplasia to carcinoma. J Obstet Gynaecol Res 1999, 25:281-286.
23. Vijayaraghavan A., Efrusy M.B., Goodman K.A., Santas C.C., Huh W.K. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol 2010, 119:237-242.